首页 > 市场调查报告书 > 製药

神经疾病

癫痫药物市场规模和预测、全球和地区份额、趋势以及按治疗、配销通路和地理分類的成长机会分析

市场调查报告书

商品编码

1389654

癫痫药物市场规模和预测、全球和地区份额、趋势以及按治疗、配销通路和地理分類的成长机会分析

Epilepsy Drugs Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment, Distribution Channel, and Geography

出版日期: 2023年11月06日 | 出版商:

The Insight Partners | 英文 139 Pages | 订单完成后即时交付

价格

简介目录图表

2022年癫痫药物市场规模为77.68亿美元，预计2030年将达到107.05亿美元；预计2022年至2030年的CAGR为4.1%。癫痫药物市场的成长主要是由癫痫盛行率的增加和老年人数量的增加所推动的。

癫痫是一种神经系统疾病，可引起癫痫发作并影响全球数百万人。癫痫药物也称为抗癫痫药物（AED），通常用于治疗癫痫，因为它有助于更好地管理癫痫患者的癫痫发作。一些抗药性癫痫患者选择其他治疗方法，例如手术和植入大脑的装置以帮助控制癫痫发作。

几种癫痫药物专利即将到期，为癫痫药物市场成长创造机会

预计未来几年癫痫药物市场的许多专利将到期。它可能会增加仿製药的渗透率，以减少医疗费用。这将为其他市场参与者创造更多机会。以下提到的是一些在未来几年内专利即将到期的药物。

公司专利专利有效期限成分处理

住友製药公司 US9206135 2026年4月21日醋酸艾斯利卡西平部分发作性癫痫发作

葛兰素史克 US7919115 2029 年 1 月 4 日拉莫三嗪癫痫

Ucb Inc USRE38551 2022 年 3 月 17 日拉科酰胺癫痫与局部发作癫痫

SK Biopharmaceuticals US7598279 2027 年 10 月 30 日 CENOBAMATE 局部性癫痫

SUPERNUS PHARMS US8877248 2027 年 11 月托吡酯癫痫缓释製剂

SUPERNUS PHARMS US9555004 2027 年 11 月托吡酯癫痫缓释製剂

SUPERNUS PHARMS US10314790 2027 年 11 月托吡酯癫痫缓释製剂

SUPERNUS PHARMS US8663683 2027 年 11 月托吡酯癫痫缓释製剂

SUPERNUS PHARMS US9622983 2027 年 11 月托吡酯癫痫缓释製剂

SUPERNUS PHARMS US8298580 2027 年 11 月托吡酯癫痫缓释製剂

SUPERNUS PHARMS US8992989 2027 年 11 月托吡酯癫痫缓释製剂

SUPERNUS PHARMS US8889191 2027 年 11 月托吡酯癫痫缓释製剂

SUPERNUS PHARMS US9549940 2027 年 11 月托吡酯癫痫缓释製剂

SUPERNUS PHARMS US8298576 2028 年 4 月托吡酯癫痫缓释製剂

基于治疗的见解

癫痫药物市场依治疗方法分为第一代抗癫痫药、第二代抗癫痫药和第三代抗癫痫药。 2022年，第二代抗癫痫药物占最大市场；第三代抗癫痫药物预计在 2022 年至 2030 年期间复合CAGR最快。第二代AED包括非氨酯、加巴喷丁、拉莫三嗪、左乙拉西坦、奥卡西平、普加巴林、卢非酰胺、司替喷醇、噻加宾、托吡酯、托吡酯、氨己烯酸和唑尼沙胺。在北美和欧洲，ZNS也被认为是第二代药物。与第一代药物相比，第二代 AED 的成本较高，这是限制其在处方集中提及的重要因素。与第一代药物相比，第二代 AED 具有更有利的副作用和更低的致畸风险。许多第一代和一些第二代 (AED) 具有酶诱导的共同特征，可以增加细胞色素 p450 酶靶向的不同底物的代谢，同时减少诱导剂的作用。

基于配销通路的见解

癫痫药物市场依配销通路分为医院药房、零售药局等。 2022年，医院药局细分市场占最大市场份额；零售药局领域预计在 2022 年至 2030 年期间CAGR最快。医院药局从不同公司采购药品，供应给医院门诊或住院治疗。医院药房通常提供适用于心臟病学、神经学、泌尿学、病理学、血液学和皮肤科的治疗和重症监护药物。医院药局是任何国家医疗保健系统的重要组成部分之一。这些药房备有癫痫药物库存，以确保患者随时可用。因此，医院药局占有相当大的癫痫药物市场规模。

在准备癫痫药物市场报告时提到的一些主要一手和二手来源包括世界卫生组织（WHO）、疾病管制与预防中心（CDC）、国家生物技术资讯中心（NCBI）、投资者介绍以及市场参与者的年度报告。

北美洲
- 我们
- 加拿大
- 墨西哥
欧洲
- 德国
- 法国
- 英国
- 义大利
- 西班牙
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地区

第 10 章：癫痫药物市场-产业格局

概述
癫痫药物市场的成长策略
无机成长策略
- 概述
有机成长策略
- 概述

第 11 章：公司简介

UCB SA
Novartis AG
Pfizer Inc
GSK Plc
Abbott Laboratories
Sanofi SA
Sumitomo Pharma America Inc.
Teva Pharmaceutical Industries Ltd
Catalyst Pharmaceuticals Inc
Alkem Laboratories Ltd

第 12 章：附录

关于我们
专业术语

简介目录图表

Product Code: TIPRE00024323

The epilepsy drugs market size was valued at US$ 7.768 billion in 2022 and is projected to reach US$ 10.705 billion by 2030; it is estimated to register a CAGR of 4.1% from 2022 to 2030. The epilepsy drugs market growth is primarily driven by the increasing prevalence of epilepsy and an increasing number of elderly people.

Epilepsy is a neurological condition that can cause seizures and affects millions of people globally. Epilepsy drugs are also known as anti-epileptic drugs (AEDs), which are commonly used for the treatment of epilepsy as it helps in the better management of seizures among epilepsy patients. Some of the patients with drugs resistance epilepsy opt for other treatment methods such as surgery and devices that are implanted in the brain to helps in seizure management.

Several Epilepsy Drugs Nearing Patent Expiration Creating Opportunities for Epilepsy Drugs Market Growth

Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.

Company Patent Patent Expiration Date Ingredient Treatment

Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy

GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy

Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures

SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies

SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy

Treatment-Based Insights

The epilepsy drugs market, by treatment, is segmented into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. In 2022, the second generation anti-epileptics segment held the largest market share; the third generation anti-epileptics is estimated to register the fastest CAGR during 2022-2030. The second-generation AEDs include felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topirate, topiramate, vigabatrin, and zonisamide. In North America and Europe, ZNS is also considered a second-generation drug. The higher cost of second-generation AEDs compared with first-generation drugs is a significant factor limiting their mention in formularies. The second-generation AEDs have a more favorable side-effect profile and a lower risk of teratogenesis compared with first-generation drugs. Many first-generation and several second-generation (AEDs) share a common feature of enzyme induction that can increase the metabolism of different substrates targeted by the cytochrome p450 enzyme, along with a decrease in the action of the inducer.

Distribution Channel-Based Insights

The epilepsy drugs market, by distribution channel, is segmented into hospital pharmacy, retail pharmacy stores, and others. In 2022, the hospital pharmacies segment held the largest market share; the retail pharmacy segment is anticipated to register the fastest CAGR during 2022-2030. Hospital pharmacies purchase pharmaceuticals from different companies and supply them to hospitals for outpatient or inpatient treatments. Hospital pharmacies usually offer therapeutic and critical care drugs that have applications in cardiology, neurology, urology, pathology, hematology, and dermatology. Hospital pharmacies are among the essential parts of the healthcare system of any country. These pharmacies maintain stocks of epilepsy drugs to ensure their ready availability for patients. Thus, hospital pharmacies hold a considerable size of the epilepsy drug market.

A few of the major primary and secondary sources referred to while preparing the report on the epilepsy drugs market are the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Investor presentations and Annual Reports of Market players.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the epilepsy drugs market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global epilepsy drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the epilepsy drugs market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Epilepsy Drugs Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 Global PEST Analysis

5. Epilepsy Drugs Market - Key Industry Dynamics

5.1 Market Drivers
- 5.1.1 Growing Prevalence of Epilepsy
- 5.1.2 Increasing Number of Elderly People
5.2 Market Restraints
- 5.2.1 Recall of Therapeutic Products
5.3 Market Opportunities
- 5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
5.4 Future Trends
- 5.4.1 Increasing Product Approvals
5.5 Impact Analysis

6. Epilepsy Drugs Market - Global Market Analysis

6.1 Epilepsy Drugs Revenue (US$ Mn), 2022 - 2030

7. Global Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Treatment

7.1 Overview
7.2 Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
7.3 First Generation Antiepileptics
- 7.3.1 Overview
- 7.3.2 First Generation Antiepileptics: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Second Generation Anti-epileptics
- 7.4.1 Overview
- 7.4.2 Second Generation Anti-epileptics: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Third Generation Anti-epileptics
- 7.5.1 Overview
- 7.5.2 Third Generation Anti-epileptics: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

8. Global Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacy
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacy: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacy Stores
- 8.4.1 Overview
- 8.4.2 Retail Pharmacy Stores: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

9. Epilepsy Drugs Market - Revenue and Forecast to 2030 - Geographic Analysis

9.1 North America: Epilepsy Drugs Market
- 9.1.1 Overview
- 9.1.2 North America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.3 North America: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.1.4 North America: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.4.1 US: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.4.1.1 Overview
    - 9.1.4.1.2 US: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.4.1.3 US: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.4.1.4 US: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.4.2 Canada: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.4.2.1 Overview
    - 9.1.4.2.2 Canada: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.4.2.3 Canada: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.4.2.4 Canada: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.4.3 Mexico: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.4.3.1 Overview
    - 9.1.4.3.2 Mexico: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.4.3.3 Mexico: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.4.3.4 Mexico: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.2 Europe: Epilepsy Drugs Market
- 9.2.1 Overview
- 9.2.2 Europe: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2.3 Europe: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.2.4 Europe: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.2.5 Europe: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
  - 9.2.5.1 Germany: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.1.1 Overview
    - 9.2.5.1.2 Germany: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.1.3 Germany: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.2.5.1.4 Germany: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.2.5.2 France: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.2.1 Overview
    - 9.2.5.2.2 France: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.2.3 France: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.2.5.2.4 France: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.2.5.3 UK: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.3.1 Overview
    - 9.2.5.3.2 UK: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.3.3 UK: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.2.5.3.4 UK: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.2.5.4 Italy: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.4.1 Overview
    - 9.2.5.4.2 Italy: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.4.3 Italy: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.2.5.4.4 Italy: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.2.5.5 Spain: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.5.1 Overview
    - 9.2.5.5.2 Spain: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.5.3 Spain: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.2.5.5.4 Spain: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.2.5.6 Rest of Europe: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.6.1 Overview
    - 9.2.5.6.2 Rest of Europe: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.6.3 Rest of Europe: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.2.5.6.4 Rest of Europe: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.3 Asia Pacific: Epilepsy Drugs Market
- 9.3.1 Overview
- 9.3.2 Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.3 Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.3.4 Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.3.5 Asia Pacific: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
  - 9.3.5.1 China: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.1.1 Overview
    - 9.3.5.1.2 China: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.1.3 China: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.3.5.1.4 China: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.3.5.2 Japan: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.2.1 Overview
    - 9.3.5.2.2 Japan: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.2.3 Japan: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.3.5.2.4 Japan: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.3.5.3 India: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.3.1 Overview
    - 9.3.5.3.2 India: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.3.3 India: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.3.5.3.4 India: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.3.5.4 Australia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.4.1 Overview
    - 9.3.5.4.2 Australia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.4.3 Australia: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.3.5.4.4 Australia: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.3.5.5 South Korea: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.5.1 Overview
    - 9.3.5.5.2 South Korea: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.5.3 South Korea: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.3.5.5.4 South Korea: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.3.5.6 Rest of Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.6.1 Overview
    - 9.3.5.6.2 Rest of Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.6.3 Rest of Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.3.5.6.4 Rest of Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.4 Middle East & Africa Epilepsy Drugs Market
- 9.4.1 Overview
- 9.4.2 Middle East & Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4.3 Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.4.4 Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.4.4.1 South Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.1.1 Overview
    - 9.4.4.1.2 South Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.1.3 South Africa: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.4.4.1.4 South Africa: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.4.4.2 Saudi Arabia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.2.1 Overview
    - 9.4.4.2.2 Saudi Arabia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.2.3 Saudi Arabia: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.4.4.2.4 Saudi Arabia: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.4.4.3 UAE: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.3.1 Overview
    - 9.4.4.3.2 UAE: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.3.3 UAE: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.4.4.3.4 UAE: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.4.1 Overview
    - 9.4.4.4.2 Rest of Middle East & Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.4.3 Rest of Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.4.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.5 South & Central America: Epilepsy Drugs Market
- 9.5.1 Overview
- 9.5.2 South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.5.3 South & Central America: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.5.4 South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.5.5 South & Central America: Epilepsy Drugs Market Share by Country - 2022 & 2030, (%)
  - 9.5.5.1 Brazil: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.5.5.1.1 Overview
    - 9.5.5.1.2 Brazil: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
    - 9.5.5.1.3 Brazil: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.5.5.1.4 Brazil: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.5.5.2 Argentina: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.5.5.2.1 Overview
    - 9.5.5.2.2 Argentina: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
    - 9.5.5.2.3 Argentina: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.5.5.2.4 Argentina: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.5.5.3 Rest of South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.5.5.3.1 Overview
    - 9.5.5.3.2 Rest of South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.5.5.3.3 Rest of South & Central America: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.5.5.3.4 Rest of South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Epilepsy Drugs Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Epilepsy Drugs Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 UCB SA
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Novartis AG
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Pfizer Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 GSK Plc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Abbott Laboratories
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Sanofi SA
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Sumitomo Pharma America Inc.
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Catalyst Pharmaceuticals Inc
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Alkem Laboratories Ltd
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. Epilepsy Drugs Segmentation
Table 2. North America Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 4. US Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 5. US Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 6. Canada Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 7. Canada Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 8. Mexico Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 9. Mexico Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 10. Europe Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 11. Europe Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 12. Germany Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 13. Germany Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. France Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 15. France Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 16. UK Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 17. UK Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 18. Italy Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 19. Italy Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 20. Spain Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 21. Spain Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 22. Rest of Europe Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Europe Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 24. Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 25. Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 26. China Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 27. China Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 28. Japan Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 29. Japan Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 30. India Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 31. India Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 32. Australia Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 33. Australia Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 34. South Korea Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 35. South Korea Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 36. Rest of Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 37. Rest of Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 38. Middle East & Africa Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 39. Middle East & Africa Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 40. South Africa Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 41. South Africa Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 42. Saudi Arabia Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 43. Saudi Arabia Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 44. UAE Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 45. UAE Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 46. Rest of Middle East & Africa Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 47. Rest of Middle East & Africa Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 48. South & Central America: Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 49. South & Central America: Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 50. Brazil: Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 51. Brazil: Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 52. Argentina: Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 53. Argentina: Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 54. Rest of South & Central America: Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 55. Rest of South & Central America: Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 56. Recent Inorganic Growth Strategies in the Epilepsy Drugs Market
Table 57. Recent Organic Growth Strategies in the Epilepsy Drugs Market
Table 58. Glossary of Terms, Epilepsy Drugs Market

List Of Figures

Figure 1. Epilepsy Drugs Segmentation, By Geography
Figure 2. Global - PEST Analysis
Figure 3. Epilepsy Drugs Market: Key Industry Dynamics
Figure 4. Epilepsy Drugs Market: Impact Analysis of Drivers and Restraints
Figure 5. Epilepsy Drugs Revenue (US$ Mn), 2022 - 2030
Figure 6. Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
Figure 7. First Generation Anti-epileptics: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Second Generation Anti-epileptics: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Third Generation Anti-epileptics: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 11. Hospital Pharmacy: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Retail Pharmacy Stores: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America: Epilepsy Drugs Market, by Key Country - Revenue (2022) (US$ Million)
Figure 15. North America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. North America: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 17. US: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Canada: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Mexico: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Europe: Epilepsy Drugs Market, by Key Country - Revenue (2022) (US$ Million)
Figure 21. Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 22. Europe: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 23. Germany: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. France: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. UK: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 26. Italy: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 27. Spain: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. Rest of Europe: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. Asia Pacific: Epilepsy Drugs Market, by Key Country - Revenue (2022) (US$ Million)
Figure 30. Asia Pacific Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)
Figure 31. Asia Pacific: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 32. China: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 33. Japan: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 34. India: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 35. Australia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 36. South Korea: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 37. Rest of Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 38. Middle East & Africa: Epilepsy Drugs Market, by Key Country - Revenue (2022) (US$ Million)
Figure 39. Middle East & Africa Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 40. Middle East & Africa: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 41. South Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 42. Saudi Arabia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 43. UAE: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 44. Rest of Middle East & Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 45. South & Central America: Epilepsy Drugs Market, By Key Country - Revenue (2022) (US$ Million)
Figure 46. South & Central America: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
Figure 47. South & Central America: Epilepsy Drugs Market Share by Country - 2022 & 2030, (%)
Figure 48. Brazil: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
Figure 49. Argentina: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
Figure 50. Rest of South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 51. Growth Strategies in the Epilepsy Drugs Market

02-2729-4219

+886-2-2729-4219

License/价格

癫痫药物市场规模和预测、全球和地区份额、趋势以及按治疗、配销通路和地理分類的成长机会分析

Epilepsy Drugs Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment, Distribution Channel, and Geography

目录

第 1 章：简介

第 2 章：执行摘要

第 3 章：研究方法

第 4 章：癫痫药物概况

第 5 章：癫痫药物市场 - 主要产业动态

第 6 章：癫痫药物市场 - 全球市场分析

第 7 章：全球癫痫药物市场 - 2030 年收入和预测 - 按治疗方法

第 8 章：全球癫痫药物市场 - 2030 年收入和预测 - 按配销通路

第 9 章：癫痫药物市场 - 2030 年收入与预测 - 地理分析

第 10 章：癫痫药物市场-产业格局

第 11 章：公司简介

第 12 章：附录

Reasons to Buy:

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Epilepsy Drugs Landscape

5. Epilepsy Drugs Market - Key Industry Dynamics

6. Epilepsy Drugs Market - Global Market Analysis

7. Global Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Treatment

8. Global Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Distribution Channel

9. Epilepsy Drugs Market - Revenue and Forecast to 2030 - Geographic Analysis

10. Epilepsy Drugs Market-Industry Landscape

11. Company Profiles

12. Appendix

List Of Tables

List Of Figures